An interventional study of HaemoCer in Breast Neoplasm Female and Mastectomy, Segmental, sponsored by Medical University of Vienna. Completed at 1 site in Austria. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-09-13.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Prevention
HaemoCer is a hemostatic agent to control bleedings during surgical procedures by accelerating natural hemostasis and is frequently applied during breast conserving surgery in women with breast cancer. There is however no adequate data available on the efficacy of HaemoCer regarding seroma formation or drainage output. The objective of this study is to investigate whether the intraoperative application of haemostatic powder (HaemoCer) in breast-conserving surgery in breast cancer patients reduces the postoperative drainage output and number of days until drain removal (number of hospitalization days).
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 136 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 177 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with previous breast-conserving surgery on the same site
-
Other: HaemoCer
Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
Total volume of postoperative drained fluid (per breast)
Time frame: 7 days
Number of days until drain removal (n)
Time frame: 7 days
Total volume of postoperative drained fluid from the axillary fossa in case of axilla surgery (sentinel lymphonodectomy, axillary dissection)
Time frame: 7 days
Rate of immediate postoperative infection on the breast surgery site
Time frame: 7 days
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna